TransMedics Group (TMDX): Analyst Targets Center on $100 With +13% Upside

Key Takeaways

• The central $100 target reflects the arithmetic mean of current analyst price targets, which recent aggregations place near $99, or roughly 13% above the latest verified price of $88.24.
• Following record third-quarter 2026 results, several firms raised targets: Canaccord Genuity to $120, Baird to $117, Needham to $110, JPMorgan to $85, and Stifel to $70, with the full range running approximately $70 to $125.
• TransMedics Group, Inc. (TMDX) reported Q3 2026 revenue of $203 million (up 41% year over year) and raised full-year revenue guidance to $764 million–$774 million.
• The strongest supporting factors are U.S. liver and heart transplant share gains, roughly 50% growth in transplant logistics, and an early entry into Europe.
• The biggest risks are margin pressure, a disclosed material weakness in internal controls, softer recent flight trends, and a stock still far below its $156 52-week high.
• For more detail on Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages for this ticker.
• Interested in automated, data-driven market signals? Explore Trending AI Robots for additional tools.

Understanding the Analyst Consensus

TransMedics Group, Inc. (TMDX) is a commercial-stage medical technology company that developed the Organ Care System (OCS), a portable organ perfusion and monitoring platform used for lung, heart, and liver transplants. Its shares carry a "Buy" consensus among the roughly 13 analysts tracked, with most ratings split between Strong Buy and Buy and a smaller Hold contingent.

The central $100 target is the arithmetic mean of the firm's current price targets, which aggregators place near $99 before rounding. Individual targets reviewed range from about $70 on the cautious end to roughly $125 on the bullish end, a wide spread that reflects genuine disagreement over how much the company's growth can offset execution and margin concerns. Post-earnings, Canaccord Genuity's William Plovanic raised his target to $120 and kept a Buy rating, while Baird lifted its target to $117 with an Outperform rating and Needham maintained Buy with a $110 target. On the more cautious side, JPMorgan raised its target to $85 but kept a Neutral rating, and Stifel held at $70 with a Hold. These figures are individual analyst expectations, not a guarantee, and they differ because analysts weight margin durability, competition, and valuation differently. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With shares at $88.24, reaching $100 would require an advance of about 13%, a modest-to-substantial move given the stock's volatility (its 52-week range spans $60.11 to $156.00). The shares jumped roughly 28% in a single session after the company's November 5, 2026 earnings report, recovering sharply from a recent low near $60 but remaining well below the prior $156 high.

The path toward the target depends on whether the company can sustain transplant procedure growth and logistics momentum while repairing margins. Q3 revenue of $203 million beat consensus of roughly $178 million, and adjusted EPS of $0.51 exceeded expectations near $0.30. Management's raised full-year guidance of $764 million–$774 million signals continued momentum, but the stock's forward P/E remains elevated, meaning execution must stay on track to justify further appreciation.

What Could Support a Move Toward the Target

• Rapid revenue growth, with Q3 up 41% year over year and transplant logistics revenue up about 50%.
• Share gains in U.S. liver and heart transplant procedures, the core of the OCS opportunity.
• Full-year guidance raised above prior levels and above the Street consensus.
• International expansion, including the company's first European transplant logistics tender win in Italy's Emilia-Romagna region.
• A cluster of post-earnings target increases, indicating improving analyst sentiment.

What Could Prevent the Target From Being Reached

• Margin pressure as the company invests in logistics infrastructure and clinical expansion.
• A disclosed material weakness in internal controls, which can weigh on investor confidence and raise execution questions.
• Softer recent aviation flight trends, which could signal near-term volatility in logistics demand.
• Valuation risk: a high forward multiple leaves little room for disappointment.
• Competition and the long road to broader OCS adoption, plus the stock's large gap to its prior peak.

Technical Levels and Market Structure

Technically, TMDX is in a recovery phase after a deep drawdown. The $100 mark is a psychologically significant round number that also sits just above the post-earnings gap, making it a natural resistance area. Below, the $76–$79 zone marks the recent breakout and gap area, a potential support level, while $60.11 is the 52-week low. The $156 52-week high represents a much more distant overhead level. Because the stock is well off its peak, overhead supply from earlier buyers could slow any sustained advance toward and beyond $100.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms vary. Investors should watch the company's next quarterly earnings and guidance, any resolution or update on the internal-controls weakness, margin trends, transplant procedure and flight volume data, and further analyst target revisions. Additional catalysts include progress on European logistics contracts and any developments in the pipeline of organ programs, as well as broader sentiment toward high-growth medical technology stocks. From what I see, monitoring these areas closely will be key.

Using AI Tools for Deeper Insights

I regularly turn to Tickeron’s AI Daily Buy/Sell Signals when tracking names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. It serves as a helpful supplement to my own fundamental and technical work, especially for volatile holdings where automated monitoring can highlight changing conditions efficiently.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume